Cellular and Molecular Mechanisms of Renal Anemia
肾性贫血的细胞和分子机制
基本信息
- 批准号:8633776
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-10-01 至 2017-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesAnemiaApplications GrantsBiologyBloodBoxingCardiovascular systemCell LineageCellsCellular biologyCharacteristicsChronic Kidney FailureComplexConsumptionDevelopmentDialysis procedureDioxygenasesEnd stage renal failureErythrocytesErythropoiesisErythropoietinFutureGene Expression ProfileGene Expression RegulationGene TargetingGenesGeneticGenetically Engineered MouseGenomeGlycoproteinsGoalsGrantHomeostasisHormonesHypoxiaHypoxia Inducible FactorHypoxia-Inducible Factor PathwayImaging technologyImpairmentIn VitroInjuryKidneyKidney FailureLaboratoriesLinkMeasurementModelingMolecularMolecular ProfilingMorbidity - disease rateNephrologyOxygenPathogenesisPathway interactionsPatient CarePatientsPhysiologicalPlasticsPopulationProcollagen-Proline DioxygenaseProductionRecombinant ErythropoietinRegulationRegulator GenesRegulatory ElementRenal Interstitial CellRenal functionReninResolutionRoleSafetySiteStressSupportive careTechniquesTransactivationUreteral obstructionVeteransWorkbHLH-PAS factor HLFcell typecostgenetic manipulationimprovedin vivoinjuredinsightinterstitialinterstitial cellkidney cellliver hypoxiamRNA Expressionmortalitynovelpublic health relevanceresponsetooltranscription factor
项目摘要
DESCRIPTION (provided by applicant):
Our long-term goal is to understand the pathogenesis of renal anemia and to develop new and safe therapies for its treatment. Anemia is a classic manifestation of advanced chronic kidney disease (CKD) and results from the diminished ability of the diseased kidney to produce adequate amounts of erythropoietin (EPO), the glycoprotein hormone that is essential for red blood production. Anemia associated with CKD or end stage renal disease (ESRD) is typically treated with recombinant EPO. The use of recombinant EPO not only represents a major cost factor in the care of patients with advanced CKD and ESRD, but also has raised significant cardiovascular safety concerns, which prompted the FDA to issue several black box warnings. While the administration of recombinant EPO to renal patients has been a hallmark of supportive care in Nephrology for more than 20 years, the molecular mechanisms that underlie the pathogenesis of renal anemia are surprisingly poorly understood. A key pathway in the regulation of renal EPO production is the hypoxia-inducible factor (HIF) pathway. Although the hypoxic induction of EPO serves as a paradigm for hypoxic gene regulation, the regulation of renal EPO synthesis under renal injury conditions is incompletely understood on both, the cellular and the molecular level. Over the last 5 years our laboratory and other groups have demonstrated that HIF-2 regulates the hypoxic induction of EPO in the kidney and liver, and that the HIF pathway can be pharmacologically targeted to treat patients with anemia. To understand the regulation of renal EPO production on a cellular and molecular level we have begun to use genetic and pharmacologic approaches to dissect the HIF/EPO axis in normal and in injured kidneys. Under this grant, we hypothesize that HIF-2 controls renal EPO production by regulating renal interstitial cell plasticity. We use genetically engineered mice to a) define the cell types in the kidney that have EPO-producing ability, b) to determine their contribution in the
regulation of erythropoiesis at baseline and under hypoxic stress conditions, c) to characterize the role of the three major HIF prolyl-hydroxylases in the regulation of renal interstitial hypoxia
responses and d) to examine HIF-2 function under renal injury conditions.
描述(由申请人提供):
我们的长期目标是了解肾性贫血的发病机制,并开发新的和安全的治疗方法。贫血是晚期慢性肾病(CKD)的典型表现,并且是由于患病肾脏产生足够量的促红细胞生成素(EPO)的能力降低所致,促红细胞生成素是红细胞生成所必需的糖蛋白激素。与CKD或终末期肾病(ESRD)相关的贫血通常用重组EPO治疗。重组EPO的使用不仅代表了晚期CKD和ESRD患者护理的主要成本因素,而且还引起了重大的心血管安全性问题,这促使FDA发布了几个黑盒警告。虽然给予肾脏患者重组EPO已经成为肾脏病学支持性治疗的标志超过20年,但令人惊讶的是,对肾性贫血发病机制的分子机制知之甚少。调节肾EPO产生的关键途径是缺氧诱导因子(HIF)途径。虽然EPO的低氧诱导作为低氧基因调控的范例,但在肾损伤条件下肾EPO合成的调控在细胞和分子水平上都不完全理解。在过去的5年里,我们的实验室和其他小组已经证明,HIF-2调节肾脏和肝脏中EPO的缺氧诱导,并且HIF途径可以被靶向治疗贫血患者。为了了解细胞和分子水平上肾EPO产生的调节,我们已经开始使用遗传学和药理学方法来解剖正常和受损肾脏中的HIF/EPO轴。根据这项研究,我们假设HIF-2通过调节肾间质细胞的可塑性来控制肾EPO的产生。我们使用基因工程小鼠来a)确定肾脏中具有EPO产生能力的细胞类型,B)确定它们在EPO产生中的作用。
c)表征三种主要HIF脯氨酰-羟化酶在肾间质缺氧调节中的作用
反应和d)在肾损伤条件下检查HIF-2功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Volker Hans Haase其他文献
Volker Hans Haase的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Volker Hans Haase', 18)}}的其他基金
Mitochondrial electron transport dysfunction: Dissecting pathomechanisms
线粒体电子传递功能障碍:剖析病理机制
- 批准号:
10679988 - 财政年份:2023
- 资助金额:
-- - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
-- - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
-- - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
-- - 项目类别: